<p>a) ACHN and 786-O cells were treated for 48 h at the indicated concentrations of Sorafenib and viability was assessed by MTT assay. Black bars indicate ACHN and white bars indicate 786-O. b) ACHN and c) 786-O cells were exposed to 10 μM Sorafenib for 16 hours. Protein extracts were blotted against with the indicated antibodies. Tubulin was used as a loading control. d) Cells were treated for 48 h with 10 μM U0126, 10 μM PD98059 or 10 μM SB203580. Viability was measured by MTT assay. Black bars indicate ACHN and white bars indicate 786-O. e) ACHN and 786-O cells were treated with Sorafenib (10 μM) in combination with the indicated inhibitors (10 μM each) for 48 h. Viability was measured by MTT assay. Black bars indicate ACHN and white bar...
The multi-kinase inhibitor sorafenib is used for the treatment of renal and hepatic carcinomas and i...
<p>(A) Sorafenib reduced the lysis ratio of NK cells in response to K562 cells (E:T = 30∶1) in a dos...
<p>(A, B) BCPAP and CG3 cells cultured in medium supplemented with 10% fetal bovine serum were treat...
<p>(<b>A</b>) To assess the effects of sorafenib, cells were exposed for 2 hours to control vehicle ...
<p>(A) Alterations in MAPKs signal transduction. HaCaT cells were incubated in medium containing 1 µ...
<p>a) Caspase 3/7 activity was evaluated in ACHN cells treated with Sorafenib for 24 hours. b) Viabi...
<p>Following incubation with increasing doses of sorafenib, viable cell counts and apoptotic cell de...
<p>A-B, HepG2 and Huh7 cells were exposed to 100 nM bufalin and/or 5 μM of sorafenib in the presence...
<p>E.G7 cells were treated with various concentrations (0–25 µM) of sorafenib for 24 hours. AlamarBl...
BACKGROUND: Sorafenib is a multi-kinase inhibitor used in the treatment of various cancers. This stu...
The anti-lymphoma activity and mechanism(s) of action of the multikinase inhibitor sorafenib were in...
<p>A. HepG2, Hep3B and SNU449 cells were treated with sorafenib (4, 8, 12, 16 µM), Apo2L/TRAIL (25 n...
The anti-lymphoma activity and mechanism(s) of action of the multikinase inhibitor sorafenib were in...
<div><p>The anti-lymphoma activity and mechanism(s) of action of the multikinase inhibitor sorafenib...
<p>a)ACHN cells were treated with Sorafenib at the indicated concentrations in the presence or absen...
The multi-kinase inhibitor sorafenib is used for the treatment of renal and hepatic carcinomas and i...
<p>(A) Sorafenib reduced the lysis ratio of NK cells in response to K562 cells (E:T = 30∶1) in a dos...
<p>(A, B) BCPAP and CG3 cells cultured in medium supplemented with 10% fetal bovine serum were treat...
<p>(<b>A</b>) To assess the effects of sorafenib, cells were exposed for 2 hours to control vehicle ...
<p>(A) Alterations in MAPKs signal transduction. HaCaT cells were incubated in medium containing 1 µ...
<p>a) Caspase 3/7 activity was evaluated in ACHN cells treated with Sorafenib for 24 hours. b) Viabi...
<p>Following incubation with increasing doses of sorafenib, viable cell counts and apoptotic cell de...
<p>A-B, HepG2 and Huh7 cells were exposed to 100 nM bufalin and/or 5 μM of sorafenib in the presence...
<p>E.G7 cells were treated with various concentrations (0–25 µM) of sorafenib for 24 hours. AlamarBl...
BACKGROUND: Sorafenib is a multi-kinase inhibitor used in the treatment of various cancers. This stu...
The anti-lymphoma activity and mechanism(s) of action of the multikinase inhibitor sorafenib were in...
<p>A. HepG2, Hep3B and SNU449 cells were treated with sorafenib (4, 8, 12, 16 µM), Apo2L/TRAIL (25 n...
The anti-lymphoma activity and mechanism(s) of action of the multikinase inhibitor sorafenib were in...
<div><p>The anti-lymphoma activity and mechanism(s) of action of the multikinase inhibitor sorafenib...
<p>a)ACHN cells were treated with Sorafenib at the indicated concentrations in the presence or absen...
The multi-kinase inhibitor sorafenib is used for the treatment of renal and hepatic carcinomas and i...
<p>(A) Sorafenib reduced the lysis ratio of NK cells in response to K562 cells (E:T = 30∶1) in a dos...
<p>(A, B) BCPAP and CG3 cells cultured in medium supplemented with 10% fetal bovine serum were treat...